- 2026-05-12
- Molecular biology reports 53(1)
- Saniya Thakur
- M V N L Chaitanya
- Sachin Kumar Singh
- Navneet Khurana
- Jubie Selvaraj
- Arya Lakshmi M
- Avijit Mazumder
- Pallav Sengupta
Background
Urolithin A (UA) is synthesized when the body metabolizes ellagic acid and ellagitannins. UA has been a widely recognized physiologically active compound throughout the previous decade. The gut microbiota affects metabolic regulators AMPK and sirtuins, initiates autophagy, and activates mitochondrial quality control, which is essential for infection resistance, intestinal health, and inflammation reduction.Methods
A preclinical study indicates that UA alters cancer cell metabolism, fortifies the intestinal barrier, safeguards the brain, and supports skeletal muscle health. UA enhances muscle endurance, mitochondrial function indicators, and cardiometabolic health without side effects or adverse reactions in preliminary human trials, primarily including the elderly and sedentary individuals. UA production exhibits significant variability due to the heterogeneity of gut flora. The existing classifications of A, B, and O kinds, absence of longitudinal data, limited trial sizes, and inconsistency between results and real-world outcomes impede the pharmaceutical advancement of UA.Results
This review commenced with an examination of UA's origins, chemical properties, gastrointestinal metabolism, absorption, molecular functions, and therapeutic potential. The literature's validity, applicability, and knowledge gaps indicate that UA is a postbiotic treatment that influences the gut microbiome's impact on mitochondrial pathways affecting various bodily systems, considering the intricate connections among inflammation, aging, and cancer. Comprehensive clinical trials are required to validate the optimal composition, dosage, and therapeutic efficacy.